

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Parini Michael</u>  (Last) (First) (Middle) 50 NORTHERN AVENUE  (Street) BOSTON MA 02210  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC / MA [VRTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, CL&AO
	3. Date of Earliest Transaction (Month/Day/Year) 04/16/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/16/2019		M		4,250	A	\$122.45	39,253	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		870	D	\$179.91 <sup>(2)(3)</sup>	38,383	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		815	D	\$181.31 <sup>(3)(4)</sup>	37,568	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		1,605	D	\$182.19 <sup>(3)(5)</sup>	35,963	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		300	D	\$183.26 <sup>(3)(6)</sup>	35,663	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		660	D	\$184.44 <sup>(3)(7)</sup>	35,003	D	
Common Stock	04/16/2019		M		2,125	A	\$90.29	37,128	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		425	D	\$179.84 <sup>(3)(8)</sup>	36,703	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		600	D	\$181.49 <sup>(3)(9)</sup>	36,103	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		600	D	\$182.24 <sup>(3)(10)</sup>	35,503	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		100	D	\$183.15	35,403	D	
Common Stock	04/16/2019		S <sup>(1)</sup>		400	D	\$184.42 <sup>(3)(11)</sup>	35,003	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					
Stock Option (Right to Buy)	\$122.45	04/16/2019		M		4,250	(12)	01/03/2026	Common Stock	4,250	\$0.00	12,750	D
Stock Option (Right to Buy)	\$90.29	04/16/2019		M		2,125	(13)	07/11/2026	Common Stock	2,125	\$0.00	10,625	D

Explanation of Responses:

1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
2. Open market sales reported on this line occurred at a weighted average price of \$179.91 (range \$179.68 to \$180.55).
3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
4. Open market sales reported on this line occurred at a weighted average price of \$181.31 (range \$180.82 to \$181.67).
5. Open market sales reported on this line occurred at a weighted average price of \$182.19 (range \$181.84 to \$182.67).
6. Open market sales reported on this line occurred at a weighted average price of \$183.26 (range \$183.13 to \$183.48).
7. Open market sales reported on this line occurred at a weighted average price of \$184.44 (range \$184.18 to \$184.71).
8. Open market sales reported on this line occurred at a weighted average price of \$179.84 (range \$179.63 to \$180.30).
9. Open market sales reported on this line occurred at a weighted average price of \$181.49 (range \$180.97 to \$181.95).
10. Open market sales reported on this line occurred at a weighted average price of \$182.24 (range \$182.06 to \$182.53).
11. Open market sales reported on this line occurred at a weighted average price of \$184.42 (range \$184.18 to \$184.71).
12. The option vests in 16 quarterly installments from 1/4/2016.
13. The option vests in 16 quarterly installments from 7/12/2016.

**Remarks:**

/s/ Omar White, Attorney-in-Fact      04/18/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**